Chemistry:Turosteride
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | 1-(4-methyl-3-oxo-4-aza-5-alpha-androstane-17-beta-carbonyl)-1,3- diisopropylurea |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C27H45N3O3 |
| Molar mass | 459.675 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Turosteride (FCE-26,073) is a selective inhibitor of the enzyme 5α-reductase which was under investigation by GlaxoSmithKline for the treatment of benign prostatic hyperplasia (BPH), but was never marketed.[1][2][3] Similarly to finasteride, turosteride is selective for the type II isoform of 5α-redcutase, with about 15-fold selectivity for it over type I isoform of the enzyme.[4][5] In animal studies it has been shown to inhibit prostate size and retard tumor growth.[2][3][6][7] It may also be useful for the treatment of acne and hair loss.[8]
See also
- 5α-Reductase inhibitor
- FCE 28,260
References
- ↑ Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. 1996. ISBN 0-412-46630-9. https://books.google.com/books?id=Z_mfTTIApVEC.
- ↑ 2.0 2.1 "Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat". The Journal of Steroid Biochemistry and Molecular Biology 46 (5): 549–555. November 1993. doi:10.1016/0960-0760(93)90181-U. PMID 8240976.
- ↑ 3.0 3.1 "Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073)". The Journal of Steroid Biochemistry and Molecular Biology 48 (2–3): 241–248. February 1994. doi:10.1016/0960-0760(94)90151-1. PMID 8142301.
- ↑ "Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors". The Journal of Steroid Biochemistry and Molecular Biology 54 (5–6): 273–279. September 1995. doi:10.1016/0960-0760(95)00134-L. PMID 7577710.
- ↑ "Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro". Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et Metabolisme 39 (2): 141–148. February 2007. doi:10.1055/s-2007-961814. PMID 17326010.
- ↑ "Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma". The Prostate 30 (2): 85–91. February 1997. doi:10.1002/(SICI)1097-0045(19970201)30:2<85::AID-PROS3>3.0.CO;2-J. PMID 9051146.
- ↑ "Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats". The Prostate 35 (4): 237–242. June 1998. doi:10.1002/(SICI)1097-0045(19980601)35:4<237::AID-PROS1>3.0.CO;2-D. PMID 9609545.
- ↑ Acne and its therapy. New York: Informa Healthcare USA. 2007. ISBN 978-0-8247-2971-4.
{{Navbox
| name = Drugs used in benign prostatic hypertrophy | title = Drugs used in [[Medicine:Benign prostatic hyperpbenign prostatic hyperplasia (G04C) | state = collapsed | listclass = hlist
| group1 = 5α-Reductase inhibitors | list1 =
| group2 = Alpha-1 blockers | list2 =
| group3 = Steroidal antiandrogens | list3 =
| group4 = Herbal products | list4 =
| group5 = Others | list5 =
}}
 |  |
